However, anti-PD-1/PD-L1 therapy is unsatisfactory in metastatic CRC (Le et al., 2015), whereas anti-CTLA-4 treatment showed a limited response rate in advanced CRC (Chung et al., 2010). This evidence concerns the gene PDCD1 and colorectal carcinoma.